Fan J G, Wei L, Zhuang H, et al. Guidelines of prevention and treatment of nonalcoholic fatty liver disease (2018, China)[J]. J Dig Dis, 2019, 20(4): 163-173. doi: 10.1111/1751-2980.12685

Chalasani N, Younossi Z, Lavine J E, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American gastroenterological association, American association for the study of liver diseases, and American college of gastroenterology[J]. Gastroenterology, 2012, 142(7): 1592-1609. doi: 10.1053/j.gastro.2012.04.001

Fan J G, Kim S U, Wong V W. New trends on obesity and NAFLD in Asia[J]. J Hepatol, 2017, 67(4): 862-873. doi: 10.1016/j.jhep.2017.06.003

Perumpail B J, Khan M A, Yoo E R, et al. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease[J]. World J Gastroenterol, 2017, 23(47): 8263-8276. doi: 10.3748/wjg.v23.i47.8263

Byrne C D, Targher G. NAFLD: a multisystem disease[J]. J Hepatol, 2015, 62(1 Suppl): S47-S64. http://europepmc.org/abstract/MED/25920090

Lee T I, Kao Y H, Chen Y C, et al. Cardiac metabolism, inflammation, and peroxisome proliferator-activated receptors modulated by 1, 25-dihydroxyvitamin D₃ in diabetic rats[J]. Int J Cardiol, 2014, 176(1): 151-157. doi: 10.1016/j.ijcard.2014.07.021

Wang H, Zhang Q, Chai Y, et al. 1, 25(OH)₂D₃ downregulates the Toll-like receptor 4-mediated inflammatory pathway and ameliorates liver injury in diabetic rats[J]. J Endocrinol Invest, 2015, 38(10): 1083-1091. doi: 10.1007/s40618-015-0287-6

Xin L L, Che B Z, Zhai B Z, et al. 1, 25-dihydroxy vitamin D₃ attenuates the oxidative stress-mediated inflammation induced by PM2. 5via the p38/NF-κB/NLRP3 pathway[J]. Inflammation, 2019, 42(2): 702-713. doi: 10.1007/s10753-018-0928-y

Horiguchi M, Hirokawa M, Abe K, et al. Pulmonary administration of 1, 25-dihydroxyvitamin D₃ to the lungs induces alveolar regeneration in a mouse model of chronic obstructive pulmonary disease[J]. J Control Release, 2016, 233: 191-197. doi: 10.1016/j.jconrel.2016.05.006

Afsal K, Harishankar M, Banurekha V V, et al. Effect of 1, 25-dihydroxy vitamin D3 on cathelicidin expression in patients with and without cavitary tuberculosis[J]. Tuberculosis (Edinb), 2014, 94(6): 599-605. doi: 10.1016/j.tube.2014.09.007

Huang J, Yang G Z, Huang Y Z, et al. 1, 25(OH)₂D₃ induced apoptosis of human hepatocellular carcinoma cells in vitro and inhibited their growth in a nude mouse xenograft model by regulating histone deacetylase 2[J]. Biochimie, 2018, 146: 28-34. doi: 10.1016/j.biochi.2017.11.012

Miyashita M, Koga K, Izumi G, et al. Effects of 1, 25-dihydroxy vitamin D₃ on endometriosis[J]. J Clin Endocrinol Metab, 2016, 101(6): 2371-2379. doi: 10.1210/jc.2016-1515

Mukherjee D, Lahiry S, Thakur S, et al. Effect of 1, 25 dihydroxy vitamin D₃ supplementation on pain relief in early rheumatoid arthritis[J]. J Family Med Prim Care, 2019, 8(2): 517-522. doi: 10.4103/jfmpc.jfmpc_446_18

Saeb S PhD, Azari H PhD, Mostafavi-Pour Z PhD, et al. 9-Cis-retinoic acid and 1, 25-dihydroxy vitamin D₃ improve the differentiation of neural stem cells into oligodendrocytes through the inhibition of the notch and wnt signaling pathways[J]. Iran J Med Sci, 2018, 43(5): 523-532. http://www.ncbi.nlm.nih.gov/pubmed/30214105

Wang Z Y, Wang Y, Xu B X, et al. Vitamin D improves immune function in immunosuppressant mice induced by glucocorticoid[J]. Biomed Rep, 2017, 6(1): 120-124. doi: 10.3892/br.2016.817

Holick M F. Vitamin D: importance in the prevention of cancers, type 1 diabetes, heart disease, and osteoporosis[J]. Am J Clin Nutr, 2004, 79(3): 362-371. doi: 10.1093/ajcn/79.3.362

Holick M F. The vitamin D deficiency pandemic: Approaches for diagnosis, treatment and prevention[J]. Rev Endocr Metab Disord, 2017, 18(2): 153-165. doi: 10.1007/s11154-017-9424-1

Jaruvongvanich V, Ahuja W, Sanguankeo A, et al. Vitamin D and histologic severity of nonalcoholic fatty liver disease: A systematic review and meta-analysis[J]. Dig Liver Dis, 2017, 49(6): 618-622. doi: 10.1016/j.dld.2017.02.003

Patel Y A, Henao R, Moylan C A, et al. Vitamin D is not associated with severity in NAFLD: results of a paired clinical and gene expression profile analysis[J]. Am J Gastroenterol, 2016, 111(11): 1591-1598. doi: 10.1038/ajg.2016.406

Roth C L, Elfers C T, Figlewicz D P, et al. Vitamin D deficiency in obese rats exacerbates nonalcoholic fatty liver disease and increases hepatic resistin and Toll-like receptor activation[J]. Hepatology, 2012, 55(4): 1103-1111. doi: 10.1002/hep.24737

Sharma S S, Jangale N M, Harsulkar A M, et al. Chronic maternal calcium and 25-hydroxyvitamin D deficiency in Wistar rats programs abnormal hepatic gene expression leading to hepatic steatosis in female offspring[J]. J Nutr Biochem, 2017, 43: 36-46. doi: 10.1016/j.jnutbio.2017.01.008

Beilfuss A, Sowa J P, Sydor S, et al. Vitamin D counteracts fibrogenic TGF-β signalling in human hepatic stellate cells both receptor-dependently and independently[J]. Gut, 2015, 64(5): 791-799. doi: 10.1136/gutjnl-2014-307024

Nelson J E, Roth C L, Wilson L A, et al. Vitamin D deficiency is associated with increased risk of non-alcoholic steatohepatitis in adults with non-alcoholic fatty liver disease: possible role for MAPK and NF-κB[J]. Am J Gastroenterol, 2016, 111(6): 852-863. doi: 10.1038/ajg.2016.51

Park D, Kwon H, Oh S W, et al. Is vitamin D an independent risk factor of nonalcoholic fatty liver disease?: a cross-sectional study of the healthy population[J]. J Korean Med Sci, 2017, 32(1): 95-101. doi: 10.3346/jkms.2017.32.1.95

Wang D, Lin H D, Xia M F, et al. Vitamin D levels are inversely associated with liver fat content and risk of non-alcoholic fatty liver disease in a Chinese middle-aged and elderly population: the Shanghai Changfeng study[J]. PLoS One, 2016, 11(6): e0157515. doi: 10.1371/journal.pone.0157515

Targher G, Bertolini L, Scala L, et al. Associations between serum 25-hydroxyvitamin D3 concentrations and liver histology in patients with non-alcoholic fatty liver disease[J]. Nutr Metab Cardiovasc Dis, 2007, 17(7): 517-524. doi: 10.1016/j.numecd.2006.04.002

Barchetta I, Carotti S, Labbadia G, et al. Liver vitamin D receptor, CYP2R1, and CYP27A1 expression: relationship with liver histology and vitamin D3 levels in patients with nonalcoholic steatohepatitis or hepatitis C virus[J]. Hepatology, 2012, 56(6): 2180-2187. doi: 10.1002/hep.25930

Nobili V, Giorgio V, Liccardo D, et al. Vitamin D levels and liver histological alterations in children with nonalcoholic fatty liver disease[J]. Eur J Endocrinol, 2014, 170(4): 547-553. doi: 10.1530/EJE-13-0609

Manco M, Ciampalini P, Nobili V. Low levels of 25-hydroxyvitamin D(3) in children with biopsy-proven nonalcoholic fatty liver disease[J]. Hepatology, 2010, 51(6): 2229-2230. http://europepmc.org/abstract/med/20513013

Kim H S, Rotundo L, Kothari N, et al. Vitamin D is associated with severity and mortality of non-alcoholic fatty liver disease: A US population-based study[J]. J Clin Transl Hepatol, 2017, 5(3): 185-192. http://www.ncbi.nlm.nih.gov/pubmed/28936398

Cheung O, Sanyal A J. Abnormalities of lipid metabolism in nonalcoholic fatty liver disease[J]. Semin Liver Dis, 2008, 28(4): 351-359. doi: 10.1055/s-0028-1091979

Mansbach C M 2nd, Gorelick F. Development and physiological regulation of intestinal lipid absorption. Ⅱ. Dietary lipid absorption, complex lipid synthesis, and the intracellular packaging and secretion of chylomicrons[J]. Am J Physiol Gastrointest Liver Physiol, 2007, 293(4): G645-G650. doi: 10.1152/ajpgi.00299.2007

Buzzetti E, Pinzani M, Tsochatzis E A. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)[J]. Metabolism, 2016, 65(8): 1038-1048. doi: 10.1016/j.metabol.2015.12.012

Barbosa-da-Silva S, Souza-Mello V, Magliano D C, et al. Singular effects of PPAR agonists on nonalcoholic fatty liver disease of diet-induced obese mice[J]. Life Sci, 2015, 127: 73-81. doi: 10.1016/j.lfs.2015.02.003

Borges C C, Salles A F, Bringhenti I, et al. Vitamin D deficiency increases lipogenesis and reduces beta-oxidation in the liver of diet-induced obese mice[J]. J Nutr Sci Vitaminol, 2018, 64(2): 106-115. doi: 10.3177/jnsv.64.106

Kong J, Li Y C. Molecular mechanism of 1, 25-dihydroxyvitamin D₃ inhibition of adipogenesis in 3T3-L1 cells[J]. Am J Physiol Endocrinol Metab, 2006, 290(5): E916-E924. doi: 10.1152/ajpendo.00410.2005

Kong M, Zhu L D, Bai L, et al. Vitamin D deficiency promotes nonalcoholic steatohepatitis through impaired enterohepatic circulation in animal model[J]. Am J Physiol Gastrointest Liver Physiol, 2014, 307(9): G883-G893. doi: 10.1152/ajpgi.00427.2013

Kong M, Zhu L D, Bai L, et al. Vitamin D deficiency promotes nonalcoholic steatohepatitis through impaired enterohepatic circulation in animal model[J]. Am J Physiol Gastrointest Liver Physiol, 2014, 307(9): G883-G893. doi: 10.1152/ajpgi.00427.2013

Zhu C G, Liu Y X, Wang H, et al. Active form of vitamin D ameliorates non-alcoholic fatty liver disease by alleviating oxidative stress in a high-fat diet rat model[J]. Endocr J, 2017, 64(7): 663-673. doi: 10.1507/endocrj.EJ16-0542

Jahn D, Dorbath D, Kircher S, et al. Beneficial effects of vitamin D treatment in an obese mouse model of non-alcoholic steatohepatitis[J]. Nutrients, 2019, 11(1): E77. doi: 10.3390/nu11010077

Han H, Cui M, You X, et al. A role of 1, 25(OH)₂D₃ supplementation in rats with nonalcoholic steatohepatitis induced by choline-deficient diet[J]. Nutr Metab Cardiovasc Dis, 2015, 25(6): 556-561. doi: 10.1016/j.numecd.2015.02.011

Foroughi M, Maghsoudi Z, Askari G. The effect of vitamin D supplementation on blood sugar and different indices of insulin resistance in patients with non-alcoholic fatty liver disease (NAFLD)[J]. Iran J Nurs Midwifery Res, 2016, 21(1): 100-104. doi: 10.4103/1735-9066.174759

Sharifi N, Amani R, Hajiani E, et al. Does vitamin D improve liver enzymes, oxidative stress, and inflammatory biomarkers in adults with non-alcoholic fatty liver disease A randomized clinical trial[J]. Endocrine, 2014, 47(1): 70-80. doi: 10.1007/s12020-014-0336-5

Kitson M T, Pham A, Gordon A, et al. High-dose vitamin D supplementation and liver histology in NASH[J]. Gut, 2016, 65(4): 717-718. http://europepmc.org/abstract/MED/26294696

Geier A, Eichinger M, Stirnimann G, et al. Treatment of non-alcoholic steatohepatitis patients with vitamin D: a double-blinded, randomized, placebo-controlled pilot study[J]. Scand J Gastroenterol, 2018, 53(9): 1114-1120. doi: 10.1080/00365521.2018.1501091